ArticleBJOG : an international journal of obstetrics and gynaecology2026
Carbetocin for Postpartum Haemorrhage Prophylaxis in All Births: A Retrospective Cohort Study Following Policy Change in Routine Uterotonic Use.
Article in BJOG : an international journal of obstetrics and gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prophylactic carbetocin versus oxytocin following vaginal delivery among women with high risk for postpartum hemorrhage: A before-and-after study.Acta obstetricia et gynecologica Scandinavica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare postpartum haemorrhage (PPH) outcomes following a change in routine prophylactic uterotonic from Oxytocin to Carbetocin.
designA retrospective cohort study with a before-after design.
settingA large tertiary maternity service in Melbourne, Australia. SAMPLE: All births that met the inclusion criteria (n = 6235) from January to June 2020 and 2021.
methodsClinical outcome data for all births in the two 6-month periods were retrieved from the electronic medical records and manually checked for accuracy. Data were statistically analysed using univariate tests and binary logistic regression.
main outcome measureWeighed blood loss (mL) and prevalence of moderate (≥ 500 mL) and severe (≥ 1000 mL) PPH. Secondary outcomes included use of additional uterotonics, blood transfusions, admission to the high-dependency care unit, and length of stay.
resultsCarbetocin was associated with significantly lower average blood loss (p < 0.001), including rates of moderate and severe PPH (p < 0.001). There were no significant differences in the use of additional uterotonics or blood transfusions following the implementation of Carbetocin. There were significant reductions in admissions to the high-dependence care unit and length of hospital stay. Secondary analyses identified that Carbetocin was associated with reduced odds of PPH for both vaginal and caesarean birth after adjusting for a range of factors that increase the risk of PPH.
conclusionCarbetocin is associated with reduced blood loss and the rate of PPH compared to Oxytocin. Associated reductions in admissions to high dependency care and length of hospital stay are likely to result in reduced maternal morbidity and lower hospital costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.